ID | 1149 |
Name of the vaccine | OmniHib |
Microbe | Bacteria |
Disease name | Haemophilus influenzae type b (Hib) |
Name of bacteria | Haemophilus influenzae |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 2 months to 5 years |
Description of the vaccine | Haemophilus b conjugate vaccine (Tetanus toxoid conjugate) (PRP-T). |
Name of the manufacturer | Pasteur Mérieux Serums & Vaccins S. A. |
Name of the manufacturing country | France |
Year of manufacture | 1993 |
Clinical Phase status | Approved |
Bacterial strain | Anaerobic gram-negative coccobacillus. |
Efficacy | NA |
Vaccine formulation | Whitish suspension |
Dosage | Four dose series (0.5 ml each). Primary series: One dose at 2, 4, and 6 months.
Booster: One dose at 15 through 18 months. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | Prevention of invasive diseases caused by diphtheria, tetanus, pertussis and H influenzae type b. |
Export | Distributed by - SmithKline Beecham Pharmaceuticals |
Approval | US FDA |
Adjuvant | NA |
Repurposing | Also for diphtheria, tetanus and pertussis. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.cdc.gov/mmwr/preview/mmwrhtml/00044501.htm |
Other name | NA |
Additional Links | https://www.rxlist.com/dtp-drug.htm#description
|